Trial Profile

A phase 1b study for cisplatin in combination with niraparib and sintilimab in the treatment of patients with advanced solid cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Niraparib (Primary) ; Sintilimab (Primary)
Indications Cervical cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

07 Jun 2022 Results of updated survival and safety data, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
14 Sep 2020 According to an Innovent Biologics media release, data will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com